Immuron to Commence US Non-Deal Institutional Investor Roadshow

NEXT STORY
Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research
PREV STORY
Outlook on the Worldwide Anti-tuberculosis Therapeutics Market to 2024 – Driven by the Rising Incidence of MDR & XDR Cases in Developing Countries
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development

HOUSTON, April 17, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company ...

author_avatar
NASDAQ Market News

Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger

WESTLAKE VILLAGE, Calif. and CHARLOTTESVILLE, Va., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics ...

author_avatar
NASDAQ Market News

Microbot Medical Showcases a Working Prototype of its Self-Cleaning Shunt

HINGHAM, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq CM: MBOT) ...

author_avatar
NASDAQ Market News